Attovia Therapeutics, Inc. - Common Stock (ATTO)
15.27
+0.27 (1.80%)
NASDAQ · Last Trade: Nov 7th, 5:35 AM EST
Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trialsmarketbeat.com
Attovia Therapeutics (NASDAQ:ATTO) reported 12-week results from a small phase 1b study of its experimental itch treatment ATTO-1310, saying a single dose produced sustained responses in patients with chronic pruritus of unknown origin and in those with high-itch atopic dermatitis.
The company plan
Via MarketBeat · November 6, 2026